Fig. 1From: A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthmaStudy design. Subjects received open-label montelukast during the run-in and treatment periods, and albuterol/salbutamol as needed to treat acute asthma symptoms. *Days 5–7 after the end of treatment. FF 50 QD fluticasone furoate 50 µg once dailyBack to article page